| Species |
Human |
| Protein Construction |
CA9/Carbonic Anhydrase IX (Gln38-Asp414)
Accession # Q16790 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CA9/Carbonic Anhydrase IX, His & Avi, Human at 1μg/ml (100μl/Well) on the plate can bind AntiCA9 Antibody, hFc Tag. Test result was comparable to standard batch. Measured by its esterase activity. The specific activity is > 20 pmol/min/µg. Test result meets the standard. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
43.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CA9 is a member of the carbonic anhydrases' family, that is often expressed in cancer cells under hypoxic condition. CA9 expression potentially contributes to the regulation of cancer cell differentiation and mediates tumour-associated genes and signalling pathways, including apoptosis, hypoxia, G2M checkpoint, PI3K/AKR/mTOR signalling and TGF-beta signalling pathways. |
| Synonyms |
CA9; CAIX; CA-IX; EC 4.2.1.1; G250; MN; P54/58N; PMW1; RCC |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
